Literature DB >> 11954856

Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis.

E Marchioni1, K Marinou-Aktipi, C Uggetti, M Bottanelli, A Pichiecchio, D Soragna, F Imbesi, A Romani, M Ceroni.   

Abstract

Randomized Controlled Trials have not let established the best pharmacological management of Acute Disseminated Encephalomyelitis (ADEM). High dose steroids are usually employed with good results, but in a few cases the clinical outcome is poor. In other patients, particularly those affected by the site restricted ADEM variants (myelitis), the disease shows a recurrent course resembling that of Multiple Sclerosis. We present here five patients, 3 of them affected by classic disseminated encephalomyelitis and 2 by a post infectious myelitis, which showed a good response to intravenous immunoglobulin (IVIg) after steroid treatment failure. In our report high dose steroids administration was substantially uneffective in all but one case, who showed a good response only during the first episode. On the contrary IVIg injection (0,4 gr/kg/day) produced a marked functional improvement in all patients starting within the first five days of drug administration and reaching a maximum within three weeks. One patient experienced a good effect nothwithstanding a steady dysability. In all cases, clinical evidence was supported by MRI controls showing improving posttreatment changes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11954856     DOI: 10.1007/pl00007836

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

Review 1.  Acute disseminated encephalomyelitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2003-01       Impact factor: 2.401

2.  Acute demyelinating disorders of the central nervous system.

Authors:  Meghan K Harris; Amir Hadi Maghzi; Masoud Etemadifar; Roger E Kelley; Eduardo Gonzalez-Toledo; Alireza Minagar
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 3.  [Acute disseminated encephalomyelitis].

Authors:  M Politi; P Papanagiotou; I Q Grunwald; C Roth; W Reith
Journal:  Radiologe       Date:  2008-06       Impact factor: 0.635

4.  An Acute Disseminated Encephalomyelitis-Like Illness in the Elderly: Neuroimaging and Neuropathology Findings.

Authors:  Ulrike W Kaunzner; Elliott Salamon; Elena Pentsova; Marc Rosenblum; Sasan Karimi; Nancy Nealon; Ehud Lavi; Dara G Jamieson
Journal:  J Neuroimaging       Date:  2016-11-29       Impact factor: 2.486

Review 5.  [Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis].

Authors:  O Stüve; S Nessler; H P Hartung; B Hemmer; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 6.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 7.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

8.  Fulminant demyelinating diseases.

Authors:  Megan R Rahmlow; Orhun Kantarci
Journal:  Neurohospitalist       Date:  2013-04

9.  Case Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review of Postvaccination Demyelination.

Authors:  Neha Kumar; Kelsey Graven; Nancy I Joseph; John Johnson; Scott Fulton; Robert Hostoffer; Hesham Abboud
Journal:  Int J MS Care       Date:  2020 Mar-Apr

10.  Unusual Neurological Manifestation of Proton Pump Inhibitor: A Case Report of Acute Disseminated Encephalomyelitis and Severe Hyponatremia After Brief Use of Proton Pump Inhibitor.

Authors:  Ahmad S Qureshi; Mohammad A Quadri; Babar Javed
Journal:  Cureus       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.